The novel EGFR mutations (p.E746_S752delinsI, p.T751_I759delinsG, p.L747_S752delinsAA) in patients with non-small cell lung cancer and the clinical treatment strategy: three case reports
Epidermal growth factor receptor (EGFR) is an established driver gene in non-small cell lung cancer (NSCLC) and the common Exon 19 del mutation (p.E746_A750 del) has exhibited remarkable responses for EGFR tyrosine kinase inhibitors (TKIs). However, there is even less comprehension of the treatment...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-09-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1129629/full |
| _version_ | 1797680793555828736 |
|---|---|
| author | Yamin Meng Xiaodong Li Lei Zhang Minhua Ye |
| author_facet | Yamin Meng Xiaodong Li Lei Zhang Minhua Ye |
| author_sort | Yamin Meng |
| collection | DOAJ |
| description | Epidermal growth factor receptor (EGFR) is an established driver gene in non-small cell lung cancer (NSCLC) and the common Exon 19 del mutation (p.E746_A750 del) has exhibited remarkable responses for EGFR tyrosine kinase inhibitors (TKIs). However, there is even less comprehension of the treatment strategy in NSCLC patients harboring uncommon Exon 19 delins mutation. Here, we identified three novel EGFR Exon 19 mutations (p.E746_S752delinsI, p.T751_I759delinsG, p.L747_S752delinsAA), and described the clinical treatment process. To our knowledge, the EGFR p.E746_S752delinsI mutation of the patient with advanced NSCLC could benefit from the treatment with Icotinib. Otherwise, for the NSCLC patients with early-stage, one harboring p.T751_I759delinsG mutation had an excellent recovery and the other harboring p.L747_S752delinsAA experienced a relapse after receiving horacoscopic radical resection, which means the patients with different Exon 19 delins mutation might have different prognosis. Our study also demonstrated that next-generation sequencing (NGS) is a crucial tool in guiding clinical treatment decisions in NSCLC. Furthermore, the real incidence of these mutation is not known, the routinely use of NGS surely will increase the detection of EGFR del-ins respect to the old tools used to screen for EGFR mutations. |
| first_indexed | 2024-03-11T23:35:26Z |
| format | Article |
| id | doaj.art-e2771ad19aef4f69ae8931e7a58efddb |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-11T23:35:26Z |
| publishDate | 2023-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-e2771ad19aef4f69ae8931e7a58efddb2023-09-20T04:30:36ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-09-011310.3389/fonc.2023.11296291129629The novel EGFR mutations (p.E746_S752delinsI, p.T751_I759delinsG, p.L747_S752delinsAA) in patients with non-small cell lung cancer and the clinical treatment strategy: three case reportsYamin Meng0Xiaodong Li1Lei Zhang2Minhua Ye3Key Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Hangzhou, Zhejiang, ChinaDepartment of Cardiothoracic Surgery, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, Zhejiang, ChinaKey Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Hangzhou, Zhejiang, ChinaDepartment of Cardiothoracic Surgery, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, Zhejiang, ChinaEpidermal growth factor receptor (EGFR) is an established driver gene in non-small cell lung cancer (NSCLC) and the common Exon 19 del mutation (p.E746_A750 del) has exhibited remarkable responses for EGFR tyrosine kinase inhibitors (TKIs). However, there is even less comprehension of the treatment strategy in NSCLC patients harboring uncommon Exon 19 delins mutation. Here, we identified three novel EGFR Exon 19 mutations (p.E746_S752delinsI, p.T751_I759delinsG, p.L747_S752delinsAA), and described the clinical treatment process. To our knowledge, the EGFR p.E746_S752delinsI mutation of the patient with advanced NSCLC could benefit from the treatment with Icotinib. Otherwise, for the NSCLC patients with early-stage, one harboring p.T751_I759delinsG mutation had an excellent recovery and the other harboring p.L747_S752delinsAA experienced a relapse after receiving horacoscopic radical resection, which means the patients with different Exon 19 delins mutation might have different prognosis. Our study also demonstrated that next-generation sequencing (NGS) is a crucial tool in guiding clinical treatment decisions in NSCLC. Furthermore, the real incidence of these mutation is not known, the routinely use of NGS surely will increase the detection of EGFR del-ins respect to the old tools used to screen for EGFR mutations.https://www.frontiersin.org/articles/10.3389/fonc.2023.1129629/fullNSCLC (non-small cell lung cancer)EGFR (epidermal growth factor receptor)mutationicotinibNGS (next-generation sequencing) |
| spellingShingle | Yamin Meng Xiaodong Li Lei Zhang Minhua Ye The novel EGFR mutations (p.E746_S752delinsI, p.T751_I759delinsG, p.L747_S752delinsAA) in patients with non-small cell lung cancer and the clinical treatment strategy: three case reports Frontiers in Oncology NSCLC (non-small cell lung cancer) EGFR (epidermal growth factor receptor) mutation icotinib NGS (next-generation sequencing) |
| title | The novel EGFR mutations (p.E746_S752delinsI, p.T751_I759delinsG, p.L747_S752delinsAA) in patients with non-small cell lung cancer and the clinical treatment strategy: three case reports |
| title_full | The novel EGFR mutations (p.E746_S752delinsI, p.T751_I759delinsG, p.L747_S752delinsAA) in patients with non-small cell lung cancer and the clinical treatment strategy: three case reports |
| title_fullStr | The novel EGFR mutations (p.E746_S752delinsI, p.T751_I759delinsG, p.L747_S752delinsAA) in patients with non-small cell lung cancer and the clinical treatment strategy: three case reports |
| title_full_unstemmed | The novel EGFR mutations (p.E746_S752delinsI, p.T751_I759delinsG, p.L747_S752delinsAA) in patients with non-small cell lung cancer and the clinical treatment strategy: three case reports |
| title_short | The novel EGFR mutations (p.E746_S752delinsI, p.T751_I759delinsG, p.L747_S752delinsAA) in patients with non-small cell lung cancer and the clinical treatment strategy: three case reports |
| title_sort | novel egfr mutations p e746 s752delinsi p t751 i759delinsg p l747 s752delinsaa in patients with non small cell lung cancer and the clinical treatment strategy three case reports |
| topic | NSCLC (non-small cell lung cancer) EGFR (epidermal growth factor receptor) mutation icotinib NGS (next-generation sequencing) |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1129629/full |
| work_keys_str_mv | AT yaminmeng thenovelegfrmutationspe746s752delinsipt751i759delinsgpl747s752delinsaainpatientswithnonsmallcelllungcancerandtheclinicaltreatmentstrategythreecasereports AT xiaodongli thenovelegfrmutationspe746s752delinsipt751i759delinsgpl747s752delinsaainpatientswithnonsmallcelllungcancerandtheclinicaltreatmentstrategythreecasereports AT leizhang thenovelegfrmutationspe746s752delinsipt751i759delinsgpl747s752delinsaainpatientswithnonsmallcelllungcancerandtheclinicaltreatmentstrategythreecasereports AT minhuaye thenovelegfrmutationspe746s752delinsipt751i759delinsgpl747s752delinsaainpatientswithnonsmallcelllungcancerandtheclinicaltreatmentstrategythreecasereports AT yaminmeng novelegfrmutationspe746s752delinsipt751i759delinsgpl747s752delinsaainpatientswithnonsmallcelllungcancerandtheclinicaltreatmentstrategythreecasereports AT xiaodongli novelegfrmutationspe746s752delinsipt751i759delinsgpl747s752delinsaainpatientswithnonsmallcelllungcancerandtheclinicaltreatmentstrategythreecasereports AT leizhang novelegfrmutationspe746s752delinsipt751i759delinsgpl747s752delinsaainpatientswithnonsmallcelllungcancerandtheclinicaltreatmentstrategythreecasereports AT minhuaye novelegfrmutationspe746s752delinsipt751i759delinsgpl747s752delinsaainpatientswithnonsmallcelllungcancerandtheclinicaltreatmentstrategythreecasereports |